O	0	3	The
O	4	17	effectiveness
O	18	20	of
B-intervention	21	31	lymphedema
I-intervention	32	36	self
I-intervention	36	37	-
I-intervention	37	47	management
O	48	50	in
O	51	54	the
O	55	65	prevention
O	66	68	of
B-condition	69	75	breast
I-condition	76	82	cancer
I-condition	82	83	-
I-condition	83	90	related
I-condition	91	101	lymphedema
O	102	105	and
O	106	113	quality
O	114	116	of
O	117	121	life
O	121	122	:
O	123	124	A
O	125	135	randomized
O	136	146	controlled
O	147	152	trial
O	152	153	.

O	154	157	The
O	158	161	aim
O	162	164	of
O	165	168	our
O	169	179	randomized
O	180	190	controlled
O	191	196	study
O	197	199	is
O	200	202	to
O	203	212	determine
O	213	216	the
O	217	223	effect
O	224	226	of
O	227	237	lymphedema
O	238	242	self
O	242	243	-
O	243	253	management
O	254	256	in
O	257	260	the
O	261	271	prevention
O	272	274	of
O	275	281	breast
O	282	288	cancer
O	288	289	-
O	289	296	related
O	297	307	lymphedema
O	308	311	and
O	312	319	quality
O	320	322	of
O	323	327	life
O	327	328	.

B-total-participants	329	334	Sixty
I-total-participants	334	335	-
I-total-participants	335	338	one
B-eligibility	339	345	breast
I-eligibility	346	352	cancer
I-eligibility	353	361	patients
O	362	366	were
O	367	375	included
O	376	378	in
O	379	382	the
O	383	388	study
O	388	389	.

O	390	392	In
O	393	396	the
O	397	409	intervention
O	410	415	group
O	415	416	,
O	417	425	patients
O	426	430	were
O	431	439	provided
O	440	448	training
O	449	452	and
O	453	458	given
O	459	460	a
O	461	469	training
O	470	477	booklet
O	478	488	describing
O	489	490	"
O	490	498	exercise
O	498	499	,
O	500	507	massage
O	508	511	and
O	512	522	prevention
O	523	530	methods
O	530	531	"
O	532	534	by
O	535	538	the
O	539	550	researchers
O	550	551	,
O	552	554	as
O	555	559	part
O	560	562	of
O	563	566	the
O	567	571	Self
O	571	572	-
O	572	582	Management
O	583	585	of
O	586	596	Lymphedema
O	597	604	Program
O	604	605	.

O	606	614	Patients
O	615	619	were
O	620	628	followed
O	629	631	by
O	632	641	telephone
O	642	645	for
O	646	647	6
O	648	654	months
O	655	658	and
O	659	666	through
O	667	674	monthly
O	675	683	clinical
O	684	689	check
O	689	690	-
O	690	693	ups
O	693	694	.

O	695	703	Patients
O	704	706	in
O	707	710	the
O	711	723	intervention
O	724	727	and
B-control	728	735	control
I-control	736	742	groups
O	743	747	were
O	748	757	evaluated
O	758	760	in
O	761	765	both
O	766	769	the
O	770	773	pre
O	773	774	-
O	774	783	operative
O	784	787	and
O	788	792	post
O	792	793	-
O	793	802	operative
O	803	810	periods
O	811	812	(
O	812	814	at
O	815	818	one
O	818	819	,
O	820	825	three
O	826	829	and
O	830	833	six
O	834	840	months
O	840	841	)
O	842	847	using
O	848	851	the
O	852	853	"
O	853	857	DASH
O	857	858	"
O	858	859	,
O	860	861	"
O	861	872	Measurement
O	873	875	of
O	876	881	Upper
O	882	891	Extremity
O	891	892	"
O	892	893	,
O	894	895	"
O	896	901	EORTC
O	902	905	QLQ
O	905	906	-
O	906	908	30
O	909	912	and
O	913	915	BR
O	915	916	-
O	916	918	23
O	919	932	questionnaire
O	932	933	"
O	933	934	.

O	935	938	The
O	939	943	Mann
O	944	951	Whitney
O	952	953	U
O	954	958	test
O	958	959	,
O	960	963	the
O	964	971	Kruskal
O	971	972	-
O	972	978	Wallis
O	979	980	H
O	981	985	test
O	985	986	,
O	987	990	the
O	991	999	Wilcoxon
O	1000	1004	test
O	1004	1005	,
O	1006	1009	and
O	1010	1013	the
O	1014	1022	Friedman
O	1023	1027	test
O	1028	1032	were
O	1033	1037	used
O	1038	1041	for
O	1042	1045	the
O	1046	1057	statistical
O	1058	1066	analysis
O	1067	1069	of
O	1070	1073	the
O	1074	1078	data
O	1078	1079	.

O	1080	1082	At
O	1083	1086	the
O	1087	1090	end
O	1091	1093	of
O	1094	1097	the
O	1098	1103	study
O	1103	1104	,
O	1105	1110	while
B-outcome	1111	1121	lymphedema
I-outcome	1122	1133	development
O	1134	1137	was
B-iv-bin-abs	1138	1141	not
I-iv-bin-abs	1142	1150	observed
O	1151	1153	in
O	1154	1157	the
O	1158	1170	intervention
O	1171	1176	group
O	1176	1177	,
B-cv-bin-percent	1178	1180	61
I-cv-bin-percent	1180	1181	.
I-cv-bin-percent	1181	1182	2
I-cv-bin-percent	1182	1183	%
O	1184	1186	of
O	1187	1190	the
O	1191	1198	control
O	1199	1207	patients
O	1208	1217	developed
O	1218	1228	lymphedema
O	1228	1229	.

O	1230	1233	The
O	1234	1244	difference
O	1245	1252	between
O	1253	1256	the
O	1257	1269	intervention
O	1270	1273	and
O	1274	1281	control
O	1282	1288	groups
O	1289	1292	for
O	1293	1296	the
O	1297	1308	development
O	1309	1311	of
O	1312	1322	lymphedema
O	1323	1326	was
O	1327	1332	found
O	1333	1335	to
O	1336	1338	be
O	1339	1352	statistically
O	1353	1364	significant
O	1365	1366	(
O	1366	1367	Ï‡
O	1367	1368	2
O	1369	1370	=
O	1371	1373	25
O	1373	1374	,
O	1374	1377	943
O	1377	1378	;
O	1379	1380	p
O	1381	1382	=
O	1383	1384	0
O	1384	1385	,
O	1385	1388	000
O	1388	1389	)
O	1389	1390	.

O	1391	1394	The
B-outcome	1395	1402	quality
I-outcome	1403	1405	of
I-outcome	1406	1410	life
O	1411	1413	of
O	1414	1417	the
O	1418	1430	intervention
O	1431	1436	group
O	1437	1440	was
O	1441	1447	higher
O	1448	1452	than
O	1453	1457	that
O	1458	1460	of
O	1461	1464	the
O	1465	1472	control
O	1473	1478	group
O	1478	1479	.

O	1480	1488	Moreover
O	1488	1489	,
O	1490	1493	the
B-outcome	1494	1501	symptom
I-outcome	1502	1508	scores
O	1509	1511	of
O	1512	1515	the
O	1516	1528	intervention
O	1529	1534	group
O	1535	1539	were
O	1540	1545	found
O	1546	1548	to
O	1549	1551	be
O	1552	1565	significantly
O	1566	1571	lower
O	1572	1576	than
O	1577	1582	those
O	1583	1585	of
O	1586	1589	the
O	1590	1597	control
O	1598	1603	group
O	1603	1604	.

O	1605	1607	As
O	1608	1609	a
O	1610	1616	result
O	1617	1619	of
O	1620	1623	our
O	1624	1632	research
O	1632	1633	,
O	1634	1636	it
O	1637	1640	can
O	1641	1643	be
O	1644	1653	concluded
O	1654	1658	that
O	1659	1662	the
O	1663	1667	Self
O	1667	1668	-
O	1668	1678	Management
O	1679	1681	of
O	1682	1692	Lymphedema
O	1693	1700	Program
O	1701	1703	is
O	1704	1713	effective
O	1714	1716	at
O	1717	1727	preventing
O	1728	1738	lymphedema
O	1739	1750	development
O	1751	1760	following
O	1761	1767	breast
O	1768	1774	cancer
O	1775	1784	treatment
O	1784	1785	.
